Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/116—Heterocyclic compounds
  • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/158—Fatty acids; Fats; Products containing oils or fats
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals

Definitions

• the invention encompasses methods for enhancing the ability of a companion animal to resist and/or overcome viral infections.
• the methods of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.
• a companion animal in need thereof a food composition comprising an effective amount of one or more antioxidants, for example, lipoic acid.
• Another embodiment encompasses methods of enhancing or increasing the immune response to a viral infection in a companion animal comprising administering to a companion animal in need thereof a food composition including an effective amount of one or more antioxidants, for example, lipoic acid.
• the invention encompasses methods of enhancing a companion animal's ability to resist or combat a viral infection comprising administering to a companion animal a food composition comprising an effective amount of lipoic acid to enhance a companion animal's ability to resist or combat a viral infection.
• the effective amount of lipoic acid to enhance a companion animal's ability to resist or combat a viral infection is at least about 25 ppm.
• the effective amount is at least about 50 ppm.
• the effective amount is at least about 100 ppm.
• the effective amount is about 100 ppm to about 600 ppm.
• the effective amount is about 100 ppm to about 200 ppm.
• the companion animal is a dog.
• the companion animal is a cat.
• the effective amount is effective to enhance innate antiviral activity in a companion animal.
• the pet food composition comprising lipoic acid is administered at least 15 days.
• the pet food composition comprising lipoic acid is administered at least 30 days.
• the pet food composition comprising lipoic acid is administered at least 45 days.
• the pet food composition comprising lipoic acid is administered daily.
• the invention also encompasses methods of treating a viral infection in a companion animal comprising administering to a companion animal in need thereof a food composition comprising an effective amount of lipoic acid.
• the effective amount of lipoic acid is at least about 25 ppm.
• the effective amount is at least about 50 ppm.
• the effective amount is at least about 100 ppm.
• the effective amount is about 100 ppm to about 600 ppm.
• the effective amount is about 100 ppm to about 200 ppm.
• the companion animal is a dog.
• the companion animal is a cat.
• the pet food composition comprising lipoic acid is administered at least 15 days.
• the pet food composition comprising lipoic acid is administered at least 30 days. [0031] In certain embodiments, the pet food composition comprising lipoic acid is administered at least 45 days.
• the pet food composition comprising lipoic acid is administered daily.
• the diet fed to the adult companion pet for example canine and feline, is the standard normal diet fed to an animal of that age.
• a typical diet for a canine of 1 to 6 years of age is the standard normal diet fed to an animal of that age.
• the inventors have also surprisingly found that the addition of one or more antioxidants, for example lipoic acid, is useful in enhancing the innate antiviral immune function in companion animals, for example, dogs and cats.
• the term "enhance” or "enhancing" when referring to antiviral immune function refers to the ability of a companion animals to have an increased immune response to an antigen and thereby be more resistant to infection or clear viral infections from the system of the companion animal faster. Accordingly, a companion animal, for example, a dog, eating a pet food containing an antioxidant, for example, lipoic acid will be more resistant to and will clear viral infections faster than an animal not consuming antioxidants.
• the component in the diet which accomplishes this is an antioxidant or mixture thereof.
• An antioxidant is a material that quenches a free radical. Examples of such materials include foods such as ginkgo biloba, citrus pulp, grape pomace, tomato pomace, carrot and spinach, all preferably dried, as well as various other materials such as beta-carotene, selenium, coenzyme QlO (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, gluthathione, taurine, N-acetylcysteine, vitamin E, vitamin C, alpha-lipoic acid, L-carnitine and the like.
• Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like vitamin E acetate, succinate, palmitate, and the like.
• the alpha form is preferable but beta, gamma and delta forms can be included.
• the D form is preferable but racemic mixtures are acceptable.
• the forms and derivatives will function in a Vitamin E like activity after ingestion by the pet.
• Vitamin C can be administered in this diet as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like, which will function in a vitamin C like activity after ingesting by the pet. They can be in any form such as liquid, semisolid, solid and heat stable form.
• Alpha-lipoic acid can be administered into the diet as alpha-lipoic acid or as a lipoate derivative as in U.S. Pat. No. 5,621,117, racemic mixtures, salts, esters or amides thereof.
• L- carnitine can be administered in the diet and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinates, as well as acetylated carnitine and the like, can be used.
• At least about 100 ppm or at least about 150 ppm of vitamin E can be used. In certain embodiments, the range of about 500 to about 1,000 ppm can be employed. Although not necessary a maximum of about 2,000 ppm or about 1,500 ppm is generally not exceeded.
• vitamin C at least about 50 ppm is used, desirably at least about 75 ppm and more desirably at least about 100 ppm.
• a nontoxic maximum can be employed.
• the quantity of alpha-lipoic acid can vary from at least about 25, desirably at least about 50 ppm, more desirably about 100 ppm.
• the range of lipoic acid that can be administered dogs is about 150 ppm to about 4500 ppm.
• the range of lipoic acid that can be administered cats is about 65 ppm to about 2600 ppm.
• Maximum quantities can vary from about 100 ppm to 600 ppm or to an amount which remains nontoxic to the pet. In certain embodiments, a range is from about 100 ppm to about 200 ppm.
• L-carnitine about 50 ppm, desirably about 200 ppm, more desirably about 300 ppm for canines are a useful minimum.
• slightly higher minimums of L-carnitine can be employed such as about 100 ppm, 200 ppm, and 500 ppm.
• a nontoxic maximum quantity can be employed, for example, less than about 5,000 ppm.
• canines lower quantities can be employed, for example, less than about 5,000 ppm.
• a preferred range is about 200 ppm to about 400 ppm.
• felines a preferred range is about 400 ppm to about 600 ppm.
• Beta-carotene at about 1-15 ppm can be employed.
• Lutein at least about 5 pm can be employed.
• Tocotrienols at least about 25 ppm can be employed.
• Coenzyme QlO at least about 25 ppm can be employed.
• S-adenosylmethionine at least about 50 ppm can be employed.
• Taurine at least about 1000 ppm can be employed.
• Soy isoflavones at least about 25 ppm can be used.
• N-acetylcysteine at least about 50 ppm can be used.
• Glutathione at least about 50 ppm can be used.
• Gingko biloba at least 50 ppm of extract can be used.
• ORAC Oxygen radical absorbing capacity
• Spinach pomace, Tomato pomace, Citrus pulp, Grape pomace, Carrot granules, Broccoli, Green tea, Ginkgo biloba and Corn gluten meal When added to the diet as 1% inclusions (for a total of 5% substitution for a low ORAC ingredient such as corn) they increased the ORAC content of the overall diet and increased the ORAC content of the plasma of the animals which ate the diet containing these components.
• any ingredient with an ORAC content >25 .mu.mole of Trolox equivalents per gram of dry matter could be used if added at 1% in combination with four other 1% ingredients for a total of 5% addition to the diet.
• RNAs were isolated from whole blood samples using the PAXgene RNA isolation kit. All measurements were done with the canine 2 Affymetrix genechips. For statistical analysis, all measurements were normalized with RMA. All analysis was preformed using Partek. An ANOVA t-test was performed for genes that are differentially expressed between the control and test foods, (at least a 20% change in expression with a pvalue ⁇ 0.05)
• IFR9, STATl and STAT2 form a complex (ISFG3) that translocates to the nucleus and up regulates the antiviral genes, interferon-induced, double stranded RNA-activated protein kinase (PKR) and 2-5A-dependent ribonuclease (RnaseL).
• PPKR interferon-induced, double stranded RNA-activated protein kinase
• RnaseL 2-5A-dependent ribonuclease
• PKR inhibits elF2Sl via phosphorylation leading to an inhibition of viral protein synthesis.
• RnaseL cleaves viral RNA inhibiting viral replication and function.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Zoology (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Animal Husbandry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Nutrition Science (AREA)
• Birds (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Physiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Virology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Fodder In General (AREA)
• Feed For Specific Animals (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=41611113

Family Applications (1)

Country Status (8)

Families Citing this family (3)

Citations (1)

Family Cites Families (8)

• 2009
  • 2009-12-16 BR BRPI0923454-3A patent/BRPI0923454A2/pt not_active Application Discontinuation
  • 2009-12-16 CA CA2746769A patent/CA2746769C/en active Active
  • 2009-12-16 US US13/140,143 patent/US20110256118A1/en not_active Abandoned
  • 2009-12-16 EP EP09793420.2A patent/EP2364098B1/en not_active Not-in-force
  • 2009-12-16 RU RU2011129309/13A patent/RU2489898C2/ru not_active IP Right Cessation
  • 2009-12-16 CN CN200980151644.8A patent/CN102245032B/zh not_active Expired - Fee Related
  • 2009-12-16 JP JP2011542373A patent/JP5731395B2/ja active Active
  • 2009-12-16 WO PCT/US2009/068230 patent/WO2010077933A1/en not_active Ceased
• 2017
  • 2017-01-19 US US15/410,351 patent/US20170128415A1/en not_active Abandoned
• 2019
  • 2019-03-26 US US16/364,535 patent/US20190216772A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events